title: Uses of drugs not described in the package insert (off-label uses).
abstract: New regulatory initiatives have been designed to ensure that new drugs and biologicals include adequate pediatric labeling for the claimed indications at the time of, or soon after, approval. However, because such labeling may not immediately be available, off-label use (or use that is not included in the approved label) of therapeutic agents is likely to remain common in the practice of pediatrics. This policy statement was written to address questions practitioners have regarding off-label use. The purpose of off-label use is to benefit the individual patient. Practitioners may use their professional judgment to determine these uses. Practitioners should understand that the Food and Drug Administration does not regulate off-label use.
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems / Q000331:legislation & jurisprudence; D002648:Child; D017277:Drug Approval; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D011307:Drug Prescriptions; D006801:Humans; D020407:Internet / Q000331:legislation & jurisprudence; D016134:Organizational Policy; D010372:Pediatrics / Q000331:legislation & jurisprudence* / Q000592:standards; D010818:Practice Patterns, Physicians' / Q000331:legislation & jurisprudence*; D012955:Societies, Medical / Q000592:standards; D014481:United States; D014486:United States Food and Drug Administration